Details of Disease

General Information of Disease (ID: DISQZGBV)

Disease Name	Juvenile idiopathic arthritis
Synonyms	juvenile chronic arthritis; rheumatoid arthritis, systemic juvenile; juvenile chronic polyarthritis; monarticular juvenile rheumatoid arthritis; pauciarticular onset juvenile chronic arthritis; acute juvenile rheumatoid arthritis; pauciarticular juvenile arthritis; systemic juvenile rheumatoid arthritis; rheumatoid arthritis, systemic juvenile, susceptibility to; JIA; juvenile rheumatoid arthritis; Arthritis, Juvenile Rheumatoid; Juvenile idiopathic arthritis; juvenile idiopathic arthritis
Disease Class	FA24: Juvenile idiopathic arthritis
Definition	Juvenile idiopathic arthritis (JIA) is the term used to describe a group of inflammatory articular disorders of unknown cause that begin before the age of 16 and last over 6 weeks. The term juvenile idiopathic arthritis was chosen to signify the absence of any known mechanism underlying the disorder and to highlight the necessity of excluding other types of arthritis occurring in well defined diseases (in particular arthritis occurring in association with infectious, inflammatory and haematooncologic diseases).
Disease Hierarchy	DIST1YEL: Arthritis DIS77ACK: Rheumatic disorder DISBBY0S: Idiopathic disease DISQZGBV: Juvenile idiopathic arthritis
ICD Code	ICD-11 ICD-11: FA24 ICD-9 ICD-9: 714.3 Expand ICD-11 'FA24 Expand ICD-10 'M08; 'M08.0; 'M08.8; 'M08.9 Expand ICD-9 714.3
Disease Identifiers	MONDO ID MONDO_0011429 MESH ID D001171 UMLS CUI C3495559 OMIM ID 618795 MedGen ID 760659 Orphanet ID 92 SNOMED CT ID 410502007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Tocilizumab	DM7J6OR	Approved	Monoclonal antibody	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Xaliproden	DM1JCW8	Phase 3	Small molecular drug	[2]
Oral human gammaglobulin	DMS4JA4	Phase 2	NA	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GP2015	DMVYFTQ	Application submitted	NA	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 82 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD14	TT6I7DC	Limited	Biomarker	[4]
CXCL1	TTLK1RW	Limited	Biomarker	[5]
CXCR4	TTBID49	Limited	Genetic Variation	[6]
IL23R	TT6H4QR	Limited	Genetic Variation	[7]
IL2RB	TT9721Y	Limited	Biomarker	[8]
OSM	TTIVXSE	Limited	Biomarker	[4]
PSMB9	TTOUSTQ	Limited	Genetic Variation	[9]
DAG1	TT4X7PG	moderate	Genetic Variation	[10]
ERAP2	TTVGS1C	moderate	Genetic Variation	[10]
GPR35	TT254XD	moderate	Genetic Variation	[10]
IL1RN	TT6GSR3	moderate	Genetic Variation	[11]
JMJD1C	TTBISK4	moderate	Genetic Variation	[12]
LRRK2	TTK0FEA	moderate	Genetic Variation	[10]
TNFSF15	TTEST6I	moderate	Genetic Variation	[10]
ALOX12	TT12ABZ	Strong	Biomarker	[4]
AQP9	TTQEI32	Strong	Biomarker	[4]
AREG	TT76B3W	Strong	Biomarker	[4]
ATIC	TT9NVXQ	Strong	Genetic Variation	[13]
BTG1	TTL7N2W	Strong	Biomarker	[4]
C9orf72	TTA4SHR	Strong	Biomarker	[4]
CACNA1I	TTQZFTH	Strong	Genetic Variation	[14]
CCL3	TT8I4WB	Strong	Altered Expression	[15]
CCR4	TT7HQD0	Strong	Biomarker	[16]
CCR5	TTJIH8Q	Strong	Genetic Variation	[17]
CD83	TTT9MRQ	Strong	Biomarker	[4]
CHIT1	TTDYX6T	Strong	Altered Expression	[18]
CLU	TTRL76H	Strong	Biomarker	[4]
CTLA4	TTI2S1D	Strong	Genetic Variation	[19]
CXCR2	TT30C9G	Strong	Biomarker	[4]
CXCR3	TT1UCIJ	Strong	Biomarker	[16]
DEK	TT1NMGV	Strong	Biomarker	[20]
DGKZ	TTSBBXL	Strong	Biomarker	[21]
DUSP1	TTG8HIM	Strong	Biomarker	[4]
DYSF	TTA7MXQ	Strong	Biomarker	[4]
EGF	TTED8JB	Strong	Biomarker	[4]
EGR1	TTE8LGD	Strong	Biomarker	[4]
ERAP1	TT60XFL	Strong	Genetic Variation	[22]
FCGR1A	TTZK4I3	Strong	Biomarker	[4]
FOS	TTOM5AU	Strong	Biomarker	[4]
FOSL2	TT689IR	Strong	Biomarker	[4]
FOXP1	TT0MUCI	Strong	Biomarker	[4]
GZMB	TTKEPHX	Strong	Altered Expression	[23]
HBEGF	TT15SL0	Strong	Biomarker	[4]
IGF1R	TTQFBMY	Strong	Biomarker	[4]
IRF1	TT4TU3L	Strong	Biomarker	[24]
JUN	TTS7IR5	Strong	Biomarker	[4]
KAT6B	TTH4VJL	Strong	Biomarker	[4]
KIF5A	TTCJPAH	Strong	Genetic Variation	[25]
KIR2DL1	TT4UXPE	Strong	Genetic Variation	[26]
KIR2DL2	TTU0P73	Strong	Genetic Variation	[26]
KIR2DL3	TTEX3SI	Strong	Genetic Variation	[26]
KIR2DS2	TTV3CFI	Strong	Genetic Variation	[26]
KLF4	TTTI53X	Strong	Biomarker	[4]
KSR1	TTHL1TV	Strong	Biomarker	[27]
MAD1L1	TTNE9U7	Strong	Biomarker	[4]
MAPK1	TT4TQBX	Strong	Biomarker	[4]
MIF	TT6804T	Strong	Genetic Variation	[28]
NR4A2	TT9HKN3	Strong	Biomarker	[4]
NR4A3	TTJQB49	Strong	Biomarker	[4]
NRG1	TTEH395	Strong	Biomarker	[4]
OLR1	TTKSND3	Strong	Biomarker	[4]
PCYT1B	TTUAIKM	Strong	Biomarker	[4]
PLAUR	TTNOSTX	Strong	Biomarker	[4]
PLK2	TT976FS	Strong	Biomarker	[4]
PLOD2	TT8MEUD	Strong	Biomarker	[4]
PRKCQ	TT1MS7X	Strong	Genetic Variation	[29]
PTPN2	TTY8PUS	Strong	Biomarker	[30]
S100A12	TTQ4ESF	Strong	Biomarker	[31]
SIK1	TT1H6LC	Strong	Biomarker	[4]
SLC22A16	TTITAVR	Strong	Biomarker	[4]
SMAD3	TTHQZV7	Strong	Genetic Variation	[10]
STAB1	TTJFEOC	Strong	Biomarker	[4]
STAT3	TTHJT3X	Strong	Biomarker	[4]
TAP1	TT7JZI8	Strong	Genetic Variation	[32]
TCF7L2	TT80QAL	Strong	Biomarker	[4]
TFPI	TT068JH	Strong	Biomarker	[4]
THBS1	TTKI0H1	Strong	Biomarker	[4]
TNFAIP3	TT5W0IO	Strong	Genetic Variation	[8]
TNFRSF11A	TT3K9S2	Strong	Biomarker	[33]
TNFRSF11B	TT2CJ75	Strong	Altered Expression	[34]
TNIK	TTPB1W3	Strong	Biomarker	[4]
TUBB2A	TTJ2PTI	Strong	Biomarker	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 82 DTT(s)

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC11A1	DT650XW	Strong	Biomarker	[35]
SLC26A2	DTFSLX5	Strong	Genetic Variation	[36]
SLC2A3	DT9SQ3L	Strong	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 4 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ACP5	DESITDW	Limited	Biomarker	[37]
ACP3	DEDW5H6	Strong	Biomarker	[4]
DHCR7	DEL7GFA	Strong	Biomarker	[30]
PER1	DE9HF0I	Strong	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 144 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ANKRD55	OT62KZII	Limited	Biomarker	[38]
BTG3	OT9ANHVT	Limited	Biomarker	[39]
C2	OTHMF4YM	Limited	Biomarker	[40]
CD247	OT45FGUX	Limited	Genetic Variation	[41]
NDEL1	OTAGFML5	Limited	Biomarker	[4]
REEP3	OTM7YVIE	Limited	Genetic Variation	[42]
ADGRL2	OTCXD2YR	moderate	Genetic Variation	[10]
ANKRD30A	OTJXYAE5	moderate	Genetic Variation	[10]
ATG16L1	OTEOYC5D	moderate	Genetic Variation	[10]
ATXN2L	OTP5M3R9	moderate	Genetic Variation	[10]
C1orf141	OTASPHL0	moderate	Genetic Variation	[10]
C4BPA	OTHNH6Y8	moderate	Biomarker	[43]
CARD14	OTADQHOV	moderate	Biomarker	[43]
CARD9	OTJ81AWD	moderate	Genetic Variation	[10]
CRB1	OTXYUNG0	moderate	Genetic Variation	[10]
FNBP1	OTSJ5KKA	moderate	Genetic Variation	[10]
FUT2	OTLXM6WI	moderate	Genetic Variation	[10]
INS-IGF2	OTZR74BO	moderate	Genetic Variation	[10]
LURAP1L	OTSJ29M5	moderate	Genetic Variation	[10]
NKD1	OTY3MO97	moderate	Genetic Variation	[10]
SUOX	OTEJQ9FC	moderate	Genetic Variation	[10]
ACRBP	OT0MK3L1	Strong	Biomarker	[4]
ADCY7	OTAWMGP3	Strong	Genetic Variation	[10]
AFF3	OTR0705Z	Strong	Genetic Variation	[19]
ANGPTL5	OTC6AFVO	Strong	Genetic Variation	[14]
ANKRD9	OT7VGO6G	Strong	Biomarker	[4]
AOPEP	OT0MMANL	Strong	Biomarker	[4]
APOBEC3A	OTYO6F5P	Strong	Biomarker	[4]
ASAP1	OT4DLRYY	Strong	Biomarker	[4]
AVL9	OTZLRZ55	Strong	Biomarker	[4]
B4GALT5	OTHMZY12	Strong	Biomarker	[4]
BEND2	OTI9Y5IC	Strong	Biomarker	[4]
C2orf88	OT59TQ6P	Strong	Biomarker	[4]
C4A	OTXMOYXU	Strong	Biomarker	[44]
C8B	OTGDJJOK	Strong	Biomarker	[45]
CALD1	OTNJKJ6Q	Strong	Biomarker	[4]
CAMSAP1	OT1N2182	Strong	Biomarker	[4]
CARD8	OTXXZYWU	Strong	Genetic Variation	[46]
CCN6	OTRFHQ2Z	Strong	Biomarker	[47]
CD226	OT4UG0KB	Strong	Genetic Variation	[38]
CD8B	OTMZ1T7J	Strong	Biomarker	[4]
CIITA	OTRJNZFO	Strong	Biomarker	[48]
CLEC16A	OTLGV5SV	Strong	Genetic Variation	[49]
CMTM2	OTSJISGF	Strong	Biomarker	[4]
COMP	OTS2FPMI	Strong	Biomarker	[37]
CREM	OTJIJ5AL	Strong	Biomarker	[4]
CRYGD	OTW29JC4	Strong	Biomarker	[50]
CSMD1	OTIVDSC4	Strong	Genetic Variation	[14]
CTTN	OTJRG4ES	Strong	Biomarker	[4]
CTTNBP2	OT4CL1EW	Strong	Genetic Variation	[14]
CXCL6	OTFTCQ4O	Strong	Biomarker	[5]
DAPK1	OTNCNUCO	Strong	Biomarker	[4]
DDIT3	OTI8YKKE	Strong	Biomarker	[4]
DUSP2	OTH54FMR	Strong	Biomarker	[4]
DUSP4	OT6WAO12	Strong	Biomarker	[4]
EBPL	OT59J1GY	Strong	Genetic Variation	[51]
ELF2	OTEI347F	Strong	Biomarker	[4]
ERAL1	OTSH78HD	Strong	Altered Expression	[52]
ETNK1	OTDKB4DQ	Strong	Biomarker	[4]
ETV6	OTCZMG61	Strong	Biomarker	[4]
FAM177A1	OTXTA14N	Strong	Genetic Variation	[53]
FAM20A	OT5Z5IW8	Strong	Biomarker	[4]
FAXDC2	OTRRS828	Strong	Biomarker	[4]
FCHSD2	OTKXLIJ6	Strong	Biomarker	[4]
FCRL3	OTIFXFWL	Strong	Genetic Variation	[54]
FLNB	OTPCOYL6	Strong	Genetic Variation	[55]
FOSB	OTW6C05J	Strong	Biomarker	[4]
GADD45A	OTDRV63V	Strong	Biomarker	[4]
GMPR	OTERWHYM	Strong	Biomarker	[4]
GNG11	OTHIXBGW	Strong	Biomarker	[4]
GP1BB	OTD7XNLL	Strong	Biomarker	[4]
HERPUD2	OTHEC6AK	Strong	Biomarker	[4]
HLA-DPA1	OT7OG7Y2	Strong	Biomarker	[8]
HLA-DPB1	OTW8JHU2	Strong	Genetic Variation	[56]
HLA-DRB3	OT5PM9N7	Strong	Biomarker	[8]
HLA-DRB5	OTUX5TWM	Strong	Biomarker	[57]
HSPA14	OTZCA5LK	Strong	Biomarker	[58]
HSPA6	OTH4S7WB	Strong	Biomarker	[4]
HYAL1	OT2SJN0X	Strong	Biomarker	[59]
IL6R	OTCQL07Z	Strong	Biomarker	[60]
IRF5	OT8SIIAP	Strong	Genetic Variation	[61]
ISG20	OTCWRJJW	Strong	Altered Expression	[62]
ITGA2B	OT4Y17PY	Strong	Biomarker	[4]
ITGB5	OT21MF51	Strong	Biomarker	[4]
ITPA	OTQ47WVR	Strong	Biomarker	[63]
KCNJ15	OTZT6EQB	Strong	Biomarker	[4]
KIR2DS4	OT00N6UJ	Strong	Biomarker	[26]
KIR3DS1	OTJWIO4T	Strong	Genetic Variation	[26]
LACC1	OT4SBHI8	Strong	Biomarker	[64]
LILRA5	OT5Q24MV	Strong	Biomarker	[4]
LRBA	OTOUZN9G	Strong	Biomarker	[65]
MAFF	OT9B7MX0	Strong	Biomarker	[4]
MAML2	OT1TSVAR	Strong	Biomarker	[4]
MAP2	OT6UYT3X	Strong	Biomarker	[4]
MEFV	OTRJ6S6K	Strong	Genetic Variation	[66]
MEX3C	OT8AJG1I	Strong	Biomarker	[4]
MS4A4A	OTWV82RP	Strong	Biomarker	[4]
MSN	OTZJ4J6G	Strong	Biomarker	[4]
MTSS1	OT5DTDO2	Strong	Biomarker	[4]
MTX1	OTLSDNZO	Strong	Biomarker	[67]
MYZAP	OTAZCNBT	Strong	Biomarker	[4]
NAA25	OTS3QVF1	Strong	Biomarker	[68]
NCR2	OT2H13BX	Strong	Altered Expression	[69]
NRBF2	OTXSUYCD	Strong	Genetic Variation	[12]
NT5C1A	OTS7UF36	Strong	Biomarker	[70]
NXF1	OTEFHXG6	Strong	Genetic Variation	[55]
PACSIN2	OTC2R00C	Strong	Biomarker	[4]
PGM5	OTEAS7OC	Strong	Biomarker	[4]
PRORP	OTWIS44P	Strong	Genetic Variation	[53]
PROS1	OTXQWNOI	Strong	Biomarker	[4]
PSMA3	OT52M10V	Strong	Genetic Variation	[71]
PSMA6	OTJ6RPX5	Strong	Genetic Variation	[71]
PSMC6	OTG8997V	Strong	Genetic Variation	[71]
PSTPIP1	OT4PGEAB	Strong	Biomarker	[72]
PTPN22	OTDCNTC3	Strong	Genetic Variation	[73]
PYDC1	OTC2DD7L	Strong	Genetic Variation	[74]
R3HDM2	OTMJ3S6J	Strong	Biomarker	[4]
RAB27A	OT9SQRWY	Strong	Genetic Variation	[75]
RASGEF1B	OT56BBU0	Strong	Biomarker	[4]
RBM45	OTWTHD77	Strong	Biomarker	[76]
RBM47	OT6W67VM	Strong	Biomarker	[4]
RBP3	OTIWM4GT	Strong	Biomarker	[77]
RERE	OT3G4GBZ	Strong	Biomarker	[4]
RHOBTB1	OTGE8K45	Strong	Biomarker	[4]
RNF103	OT9DOB4H	Strong	Biomarker	[4]
SAG	OTDNS3ZQ	Strong	Biomarker	[77]
SEC14L2	OTJST64D	Strong	Genetic Variation	[55]
SERPINA2	OT7UW9HA	Strong	Altered Expression	[37]
SH2D2A	OTQSKW7U	Strong	Genetic Variation	[78]
SH3BGRL2	OTOX4XT7	Strong	Biomarker	[4]
SIAE	OTDQUESH	Strong	Genetic Variation	[79]
SIPA1L1	OTS6M0KO	Strong	Biomarker	[4]
STIM1	OT8CLQ1W	Strong	Biomarker	[4]
STXBP2	OTX8GUC4	Strong	Biomarker	[80]
SUMO4	OT9B447E	Strong	Genetic Variation	[81]
TFDP1	OT6RZ7VT	Strong	Biomarker	[4]
TIMMDC1	OTIK4I5R	Strong	Genetic Variation	[12]
TLR10	OTQ1KVJO	Strong	Genetic Variation	[82]
TNFAIP6	OT1SLUZH	Strong	Biomarker	[4]
TNFAIP8	OT1G9297	Strong	Biomarker	[4]
TNFRSF10C	OTVHOL9B	Strong	Biomarker	[4]
TREML1	OTMJD2HI	Strong	Biomarker	[4]
TSBP1	OT5GE8IO	Strong	Genetic Variation	[83]
TTLL5	OTUKOVEM	Strong	Biomarker	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 144 DOT(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT00110708) Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism. U.S. National Institutes of Health.
4	Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.Arthritis Rheum. 2009 Jul;60(7):2113-23. doi: 10.1002/art.24534.
5	Secretion of pro-inflammatory cytokines and chemokines and loss of regulatory signals by fibroblast-like synoviocytes in juvenile idiopathic arthritis.Proteomics Clin Appl. 2017 May;11(5-6):1600088. doi: 10.1002/prca.201600088. Epub 2017 Jan 17.
6	Variants in CXCR4 associate with juvenile idiopathic arthritis susceptibility.BMC Med Genet. 2016 Mar 22;17:24. doi: 10.1186/s12881-016-0285-3.
7	IL23R gene polymorphism with juvenile idiopathic arthritis and its association with serum IL-17A.Int J Rheum Dis. 2016 Nov;19(11):1189-1196. doi: 10.1111/1756-185X.12674. Epub 2015 May 27.
8	Immunogenetics of juvenile idiopathic arthritis: A comprehensive review.J Autoimmun. 2015 Nov;64:113-24. doi: 10.1016/j.jaut.2015.08.002. Epub 2015 Aug 21.
9	Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis.J Rheumatol. 1996 Apr;23(4):747-52.
10	Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases.Nat Med. 2015 Sep;21(9):1018-27. doi: 10.1038/nm.3933. Epub 2015 Aug 24.
11	IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.Arthritis Rheumatol. 2018 Aug;70(8):1319-1330. doi: 10.1002/art.40498. Epub 2018 Jun 28.
12	Genome-wide association analysis of juvenile idiopathic arthritis identifies a new susceptibility locus at chromosomal region 3q13.Arthritis Rheum. 2012 Aug;64(8):2781-91. doi: 10.1002/art.34429.
13	Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis.Ann Rheum Dis. 2011 Aug;70(8):1395-400. doi: 10.1136/ard.2010.146191. Epub 2011 Apr 22.
14	Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases.Pharmacogenomics J. 2014 Aug;14(4):356-64. doi: 10.1038/tpj.2014.3. Epub 2014 Apr 8.
15	Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells.Arthritis Res Ther. 2006;8(2):R50. doi: 10.1186/ar1913. Epub 2006 Feb 28.
16	Coexpression of chemokine receptors CCR5, CXCR3, and CCR4 and ligands for P- and E-selectin on T lymphocytes of patients with juvenile idiopathic arthritis.Arthritis Rheum. 2011 Nov;63(11):3467-76. doi: 10.1002/art.30521.
17	Association between the chemokine receptor 5 delta32 polymorphism and rheumatoid arthritis: a meta-analysis.Mod Rheumatol. 2013 Mar;23(2):304-10. doi: 10.1007/s10165-012-0665-2. Epub 2012 May 27.
18	Chitotriosidase activity in juvenile idiopathic arthritis.Rheumatol Int. 2008 Jul;28(9):949-50. doi: 10.1007/s00296-008-0558-z. Epub 2008 Mar 7.
19	Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis.Genes Immun. 2010 Mar;11(2):194-8. doi: 10.1038/gene.2009.105. Epub 2010 Jan 14.
20	High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.Arthritis Rheumatol. 2018 Apr;70(4):594-605. doi: 10.1002/art.40404. Epub 2018 Feb 22.
21	Diacylglycerol Kinase Regulates Macrophage Responses in Juvenile Arthritis and Cytokine Storm Syndrome Mouse Models.J Immunol. 2020 Jan 1;204(1):137-146. doi: 10.4049/jimmunol.1900721. Epub 2019 Dec 4.
22	Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis.Arthritis Res Ther. 2011 Jan 31;13(1):R12. doi: 10.1186/ar3235.
23	Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome.Arthritis Rheumatol. 2015 Nov;67(11):3037-46. doi: 10.1002/art.39295.
24	No evidence for genetic association of interferon regulatory factor 1 in juvenile idiopathic arthritis.Arthritis Rheum. 2007 Mar;56(3):972-6. doi: 10.1002/art.22425.
25	Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis.Ann Rheum Dis. 2010 Jun;69(6):1049-53. doi: 10.1136/ard.2009.110650. Epub 2009 Aug 11.
26	Natural killer cell activity and frequency of killer cell immunoglobulin-like receptors in children with different forms of juvenile idiopathic arthritis.Pediatr Allergy Immunol. 2013 Nov;24(7):691-6. doi: 10.1111/pai.12130.
27	Network analysis identifies protein clusters of functional importance in juvenile idiopathic arthritis.Arthritis Res Ther. 2014 May 8;16(3):R109. doi: 10.1186/ar4559.
28	Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids.Clin Exp Rheumatol. 2007 Sep-Oct;25(5):775-81.
29	he genetics of juvenile idiopathic arthritis: Searching for new susceptibility loci.Mol Med Rep. 2017 Dec;16(6):8793-8798. doi: 10.3892/mmr.2017.7733. Epub 2017 Oct 5.
30	Epistasis amongst PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile idiopathic arthritis.J Steroid Biochem Mol Biol. 2015 Jan;145:113-20. doi: 10.1016/j.jsbmb.2014.10.012. Epub 2014 Oct 18.
31	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.Arthritis Rheumatol. 2019 Mar;71(3):451-459. doi: 10.1002/art.40727. Epub 2019 Jan 24.
32	HLA-DRB1, TAP2/TAP1, and HLA-DPB1 haplotypes in Finnish juvenile idiopathic arthritis: more complexity within the MHC.Genes Immun. 2004 Nov;5(7):562-71. doi: 10.1038/sj.gene.6364129.
33	Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?.Scand J Rheumatol. 2008 Nov-Dec;37(6):439-44. doi: 10.1080/03009740802116224.
34	Is it possible to predict a risk of osteoporosis in patients with juvenile idiopathic arthritis? A study of serum levels of bone turnover markers.Acta Biochim Pol. 2018;65(2):297-302. doi: 10.18388/abp.2017_2561. Epub 2018 May 30.
35	Iron and infection: effects of host iron status and the iron-regulatory genes haptoglobin and NRAMP1 (SLC11A1) on host-pathogen interactions in tuberculosis and HIV.Clin Sci (Lond). 2006 May;110(5):503-24. doi: 10.1042/CS20050273.
36	Positive association of SLC26A2 gene polymorphisms with susceptibility to systemic-onset juvenile idiopathic arthritis.Arthritis Rheum. 2007 Apr;56(4):1286-91. doi: 10.1002/art.22444.
37	Juvenile idiopathic arthritis patients have a distinct cartilage and bone biomarker profile that differs from healthy and knee-injured children.Clin Exp Rheumatol. 2020 Mar-Apr;38(2):355-365. doi: 10.55563/clinexprheumatol/ck090i. Epub 2019 Oct 30.
38	CD226 (DNAM-1) is associated with susceptibility to juvenile idiopathic arthritis.Ann Rheum Dis. 2015 Dec;74(12):2193-8. doi: 10.1136/annrheumdis-2013-205138. Epub 2014 Jul 23.
39	Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.Arthritis Rheumatol. 2018 Oct;70(10):1685-1694. doi: 10.1002/art.40544. Epub 2018 Aug 21.
40	Inherited deficiency of the second component of complement. Rheumatic disease associations.J Clin Invest. 1976 Oct;58(4):853-61. doi: 10.1172/JCI108538.
41	Investigation of juvenile idiopathic arthritis susceptibility loci: results from a Greek population.Hum Immunol. 2013 Sep;74(9):1194-8. doi: 10.1016/j.humimm.2013.06.018. Epub 2013 Jun 15.
42	The DNA methylation landscape of CD4(+) T cells in oligoarticular juvenile idiopathic arthritis.J Autoimmun. 2018 Jan;86:29-38. doi: 10.1016/j.jaut.2017.09.010. Epub 2017 Sep 29.
43	Comparative analysis of conventional and biological treatment in healing of bone disease.Saudi J Biol Sci. 2018 Jan;25(1):162-166. doi: 10.1016/j.sjbs.2017.02.003. Epub 2017 Feb 24.
44	Partial C4 deficiency in juvenile idiopathic arthritis patients.J Clin Rheumatol. 2007 Oct;13(5):256-60. doi: 10.1097/RHU.0b013e318156b9e3.
45	Deficiency of the beta subunit of the eighth component of complement presenting as arthritis and exanthem.Arthritis Rheum. 1994 Nov;37(11):1704-6. doi: 10.1002/art.1780371121.
46	Association of NLRP3 and CARD8 genetic polymorphisms with juvenile idiopathic arthritis in a Taiwanese population.Scand J Rheumatol. 2014;43(2):146-52. doi: 10.3109/03009742.2013.834962. Epub 2013 Dec 3.
47	Wnt-1-inducible signaling pathway protein 3 and susceptibility to juvenile idiopathic arthritis.Arthritis Rheum. 2005 Nov;52(11):3548-53. doi: 10.1002/art.21392.
48	The MHC2TA-168A/G and +1614G/C polymorphisms and risk for multiple sclerosis or chronic inflammatory arthropathies.Tissue Antigens. 2007 Sep;70(3):247-51. doi: 10.1111/j.1399-0039.2007.00876.x.
49	A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis.Ann Rheum Dis. 2010 Aug;69(8):1471-4. doi: 10.1136/ard.2009.114934. Epub 2009 Sep 3.
50	Antibodies to Cyclic Citrullinated Peptides in Patients With Juvenile Idiopathic Arthritis and Patients With Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype.Arthritis Rheumatol. 2017 Jul;69(7):1387-1395. doi: 10.1002/art.40117. Epub 2017 Jun 5.
51	Self-rated walking disability and dynamic ankle joint stiffness in children and adolescents with Juvenile Idiopathic Arthritis receiving intraarticular corticosteroid joint injections of the foot.Gait Posture. 2019 Jan;67:257-261. doi: 10.1016/j.gaitpost.2018.10.024. Epub 2018 Oct 21.
52	Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.Arthritis Care Res (Hoboken). 2020 Apr;72(4):507-516. doi: 10.1002/acr.23853.
53	Identification of a novel candidate locus for juvenile idiopathic arthritis at 14q13.2 in the Latvian population by association analysis with microsatellite markers.DNA Cell Biol. 2010 Sep;29(9):543-51. doi: 10.1089/dna.2009.0970.
54	The FCRL3 -169T>C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases.Ann Rheum Dis. 2008 Sep;67(9):1287-91. doi: 10.1136/ard.2007.077826. Epub 2007 Dec 7.
55	Polymorphism of human major histocompatibility complex-encoded transporter associated with antigen processing (TAP) genes and susceptibility to juvenile rheumatoid arthritis.Hum Immunol. 1994 Jan;39(1):54-60. doi: 10.1016/0198-8859(94)90101-5.
56	HLA-DRB1 alleles and juvenile idiopathic arthritis: Diagnostic clues emerging from a meta-analysis.Autoimmun Rev. 2017 Dec;16(12):1230-1236. doi: 10.1016/j.autrev.2017.10.007. Epub 2017 Oct 14.
57	HLA antigen frequencies in juvenile chronic arthritis.Scand J Rheumatol. 1985;14(2):209-16. doi: 10.3109/03009748509165506.
58	Peripheral blood mononuclear cell responses to heat shock proteins and their derived synthetic peptides in juvenile idiopathic arthritis patients.Inflamm Res. 2006 Apr;55(4):153-9. doi: 10.1007/s00011-006-0065-1.
59	A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis.J Inherit Metab Dis. 2011 Oct;34(5):1013-22. doi: 10.1007/s10545-011-9343-3. Epub 2011 May 11.
60	Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.Clin Rheumatol. 2018 Jul;37(7):1807-1816. doi: 10.1007/s10067-018-4071-9. Epub 2018 Apr 13.
61	Association of interferon regulatory factor 5 (IRF5) gene polymorphisms with juvenile idiopathic arthritis.Clin Rheumatol. 2018 Oct;37(10):2661-2665. doi: 10.1007/s10067-018-4010-9. Epub 2018 Feb 8.
62	Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis.J Immunol. 2014 Sep 15;193(6):2699-708. doi: 10.4049/jimmunol.1400599. Epub 2014 Aug 4.
63	5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis.Rheumatol Int. 2015 Apr;35(4):619-27. doi: 10.1007/s00296-014-3131-y. Epub 2014 Sep 21.
64	Biallelic loss-of-function LACC1/FAMIN Mutations Presenting as Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis.Sci Rep. 2019 Mar 14;9(1):4579. doi: 10.1038/s41598-019-40874-2.
65	Evolving spectrum of LRBA deficiency-associated chronic arthritis: is there a causative role in juvenile idiopathic arthritis?.Clin Exp Rheumatol. 2017 Mar-Apr;35(2):327-329. Epub 2017 Jan 27.
66	Progression of palindromic rheumatism to juvenile idiopathic arthritis in a Japanese girl carrying heterozygous L110P-E148Q substitutions of MEFV gene.Mod Rheumatol. 2018 Mar;28(2):365-368. doi: 10.3109/14397595.2015.1106639. Epub 2015 Nov 20.
67	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy inChildren With Polyarticular Forms of Juvenile IdiopathicArthritis With Clinically Inactive Disease.Arthritis Rheumatol. 2018 Sep;70(9):1508-1518. doi: 10.1002/art.40509. Epub 2018 Jul 25.
68	Variants in TNFAIP3, STAT4, and C12orf30 loci associated with multiple autoimmune diseases are also associated with juvenile idiopathic arthritis.Arthritis Rheum. 2009 Jul;60(7):2124-30. doi: 10.1002/art.24618.
69	Innate Lymphoid Cells and T Cells Contribute to the Interleukin-17A Signature Detected in the Synovial Fluid of Patients With Juvenile Idiopathic Arthritis.Arthritis Rheumatol. 2019 Mar;71(3):460-467. doi: 10.1002/art.40731. Epub 2019 Jan 28.
70	Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.Ann Rheum Dis. 2018 May;77(5):714-719. doi: 10.1136/annrheumdis-2017-212436. Epub 2018 Jan 23.
71	Juvenile idiopathic arthritis subtype- and sex-specific associations with genetic variants in the PSMA6/PSMC6/PSMA3 gene cluster.Pediatr Neonatol. 2014 Oct;55(5):393-403. doi: 10.1016/j.pedneo.2014.01.007. Epub 2014 May 27.
72	Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis.Arthritis Rheum. 2008 Jul;58(7):2142-6. doi: 10.1002/art.23604.
73	STAT4 rs7574865 G/T and PTPN22 rs2488457 G/C polymorphisms influence the risk of developing juvenile idiopathic arthritis in Han Chinese patients.PLoS One. 2015 Mar 17;10(3):e0117389. doi: 10.1371/journal.pone.0117389. eCollection 2015.
74	Inflammasomes and human autoimmunity: A comprehensive review.J Autoimmun. 2015 Jul;61:1-8. doi: 10.1016/j.jaut.2015.05.001. Epub 2015 May 23.
75	Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis.Arthritis Rheum. 2008 Mar;58(3):869-74. doi: 10.1002/art.23270.
76	Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects.Arthritis Rheum. 2010 Jun;62(6):1781-91. doi: 10.1002/art.27424.
77	Cellular immune responses of patients with juvenile chronic arthritis to retinal antigens and their synthetic peptides.Immunol Res. 1996;15(1):74-83. doi: 10.1007/BF02918285.
78	Genetic association between juvenile rheumatoid arthritis and polymorphism in the SH2D2A gene.Genes Immun. 2004 Jun;5(4):310-2. doi: 10.1038/sj.gene.6364093.
79	SIAE Rare Variants in Juvenile Idiopathic Arthritis and Primary Antibody Deficiencies.J Immunol Res. 2017;2017:1514294. doi: 10.1155/2017/1514294. Epub 2017 Aug 16.
80	Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis.Arthritis Rheumatol. 2014 Dec;66(12):3486-95. doi: 10.1002/art.38793.
81	The type 1 diabetes susceptibility gene SUMO4 at IDDM5 is not associated with susceptibility to rheumatoid arthritis or juvenile idiopathic arthritis.Rheumatology (Oxford). 2005 Nov;44(11):1390-3. doi: 10.1093/rheumatology/kei041. Epub 2005 Sep 13.
82	Association of toll-like receptor 10 polymorphisms with paediatric idiopathic uveitis in Han Chinese.Br J Ophthalmol. 2020 Oct;104(10):1467-1471. doi: 10.1136/bjophthalmol-2019-314483. Epub 2019 Jul 4.
83	Association of the TRAF1-C5 locus on chromosome 9 with juvenile idiopathic arthritis.Arthritis Rheum. 2008 Jul;58(7):2206-7. doi: 10.1002/art.23603.